Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and in vivo activity.

Arico-Muendel CC, Belanger B, Benjamin D, Blanchette HS, Caiazzo TM, Centrella PA, DeLorey J, Doyle EG, Gradhand U, Griffin ST, Hill S, Labenski MT, Morgan BA, O'Donovan G, Prasad K, Skinner S, Taghizadeh N, Thompson CD, Wakefield J, Westlin W, White KF.

Drug Metab Dispos. 2013 Apr;41(4):814-26. doi: 10.1124/dmd.112.048355. Epub 2013 Jan 25.

2.

Carbamate analogues of fumagillin as potent, targeted inhibitors of methionine aminopeptidase-2.

Arico-Muendel CC, Benjamin DR, Caiazzo TM, Centrella PA, Contonio BD, Cook CM, Doyle EG, Hannig G, Labenski MT, Searle LL, Lind K, Morgan BA, Olson G, Paradise CL, Self C, Skinner SR, Sluboski B, Svendsen JL, Thompson CD, Westlin W, White KF.

J Med Chem. 2009 Dec 24;52(24):8047-56. doi: 10.1021/jm901260k.

PMID:
19929003
3.

Involution of collagen-induced arthritis with an angiogenesis inhibitor, PPI-2458.

Brahn E, Schoettler N, Lee S, Banquerigo ML.

J Pharmacol Exp Ther. 2009 May;329(2):615-24. doi: 10.1124/jpet.108.148478. Epub 2009 Feb 13.

4.

Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI-2458.

Hannig G, Bernier SG, Hoyt JG, Doyle B, Clark E, Karp RM, Lorusso J, Westlin WF.

Arthritis Rheum. 2007 Mar;56(3):850-60.

5.

A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo.

Cooper AC, Karp RM, Clark EJ, Taghizadeh NR, Hoyt JG, Labenski MT, Murray MJ, Hannig G, Westlin WF, Thompson CD.

Clin Cancer Res. 2006 Apr 15;12(8):2583-90.

6.

A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis.

Bernier SG, Lazarus DD, Clark E, Doyle B, Labenski MT, Thompson CD, Westlin WF, Hannig G.

Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10768-73. Epub 2004 Jul 12.

7.

Inhibition of melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458.

Hannig G, Lazarus DD, Bernier SG, Karp RM, Lorusso J, Qiu D, Labenski MT, Wakefield JD, Thompson CD, Westlin WF.

Int J Oncol. 2006 Apr;28(4):955-63.

PMID:
16525646
8.

Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells.

Turk BE, Griffith EC, Wolf S, Biemann K, Chang YH, Liu JO.

Chem Biol. 1999 Nov;6(11):823-33.

9.

Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2.

Griffith EC, Su Z, Niwayama S, Ramsay CA, Chang YH, Liu JO.

Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15183-8.

10.

An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis.

Lazarus DD, Doyle EG, Bernier SG, Rogers AB, Labenski MT, Wakefield JD, Karp RM, Clark EJ, Lorusso J, Hoyt JG, Thompson CD, Hannig G, Westlin WF.

Inflamm Res. 2008 Jan;57(1):18-27. doi: 10.1007/s00011-007-7075-5.

PMID:
18209961
11.

Fumagalone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis.

Zhou G, Tsai CW, Liu JO.

J Med Chem. 2003 Jul 31;46(16):3452-4.

PMID:
12877582
12.

cis-fumagillin, a new methionine aminopeptidase (type 2) inhibitor produced by Penicillium sp. F2757.

Kwon JY, Jeong HW, Kim HK, Kang KH, Chang YH, Bae KS, Choi JD, Lee UC, Son KH, Kwon BM.

J Antibiot (Tokyo). 2000 Aug;53(8):799-806.

13.

Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin.

Griffith EC, Su Z, Turk BE, Chen S, Chang YH, Wu Z, Biemann K, Liu JO.

Chem Biol. 1997 Jun;4(6):461-71.

PMID:
9224570
15.
16.

Correlation of tumor growth suppression and methionine aminopetidase-2 activity blockade using an orally active inhibitor.

Wang J, Tucker LA, Stavropoulos J, Zhang Q, Wang YC, Bukofzer G, Niquette A, Meulbroek JA, Barnes DM, Shen J, Bouska J, Donawho C, Sheppard GS, Bell RL.

Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1838-43. doi: 10.1073/pnas.0708766105. Epub 2008 Feb 5.

17.

Orally active fumagillin analogues: transformations of a reactive warhead in the gastric environment.

Arico-Muendel CC, Blanchette H, Benjamin DR, Caiazzo TM, Centrella PA, DeLorey J, Doyle EG, Johnson SR, Labenski MT, Morgan BA, O'Donovan G, Sarjeant AA, Skinner S, Thompson CD, Griffin ST, Westlin W, White KF.

ACS Med Chem Lett. 2013 Feb 22;4(4):381-6. doi: 10.1021/ml3003633. eCollection 2013 Apr 11.

18.

Methionine aminopeptidase 2 is a new target for the metastasis-associated protein, S100A4.

Endo H, Takenaga K, Kanno T, Satoh H, Mori S.

J Biol Chem. 2002 Jul 19;277(29):26396-402. Epub 2002 May 6.

19.

Angiogenesis inhibitors specific for methionine aminopeptidase 2 as drugs for malaria and leishmaniasis.

Zhang P, Nicholson DE, Bujnicki JM, Su X, Brendle JJ, Ferdig M, Kyle DE, Milhous WK, Chiang PK.

J Biomed Sci. 2002 Jan-Feb;9(1):34-40.

PMID:
11810023
20.

Highly potent inhibitors of methionine aminopeptidase-2 based on a 1,2,4-triazole pharmacophore.

Marino JP Jr, Fisher PW, Hofmann GA, Kirkpatrick RB, Janson CA, Johnson RK, Ma C, Mattern M, Meek TD, Ryan MD, Schulz C, Smith WW, Tew DG, Tomazek TA Jr, Veber DF, Xiong WC, Yamamoto Y, Yamashita K, Yang G, Thompson SK.

J Med Chem. 2007 Aug 9;50(16):3777-85. Epub 2007 Jul 18.

PMID:
17636946
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk